Stockreport

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Abpro Holdings, Inc  (ABP) 
NASDAQ:AMEX Investor Relations: abpro.com/contact
PDF FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro’s gl [Read more]